The treatment approach to patients 80 years of age and older with gastroesophageal cancer at Baylor Scott and White in Temple, Texas, has historically favored conservative measures in the form of palliation and observation. To evaluate this trend in practice, the administered treatments and subsequent patient outcomes of this group were retrospectively reviewed. The study group included all patients 80 years of age and older with a diagnosis of gastroesophageal cancer seen at our facility between 1991 and 2010. Of the 117 cases, 49% received none of the available treatment modalities. The median overall survival (OS) of patients who received treatment, however, was significantly longer than the OS of those who did not, regardless of modality. Specifically, surgical intervention offered an almost double median OS compared with no therapy (6.8 vs. 3.9 months, respectively; P = 0.02); chemotherapy, an almost 4-fold OS benefit (14.8 vs. 3.9 months; P = 0.03); and radiation therapy, a >3-fold OS benefit (11.1 vs. 3.5 months; P = 0.04). These results further substantiate chronological age as an inaccurate predictor of treatment benefit, and age alone should not dictate the administration or withholding of available treatment options. T he treatment approach to patients 80 years of age and older with gastroesophageal cancer at Baylor Scott and White in Temple, Texas, has historically favored conservative measures in the form of palliation and observation. To evaluate this trend in practice, the administered treatment(s) and subsequent patient outcomes of this group were retrospectively reviewed.
METHODS
Th e study group included all patients 80 years of age and older with a diagnosis of gastroesophageal cancer, regardless of stage (I-IV) or performance status (Eastern Cooperative Oncology Group 0-4), seen in our facility from 1991 to 2010. Th e treatment course (i.e., surgery, chemotherapy, radiation therapy, or any combination of these modalities) and overall survival in months were retrospectively reviewed.
Descriptive statistics were reported using minimum, 25th percentile, median (or 50th percentile), mean, 75th percentile, maximum, and standard deviation for continuous variables. Categorical variables were described as counts and percentages. Kaplan-Meier curves were constructed for gender, age group, chemotherapy, radiation, and surgery. Cox proportional hazard models were fi tted to the data. Th e variables included in the model were all variables with a P value < 0.25 in the univariate survival analysis. Residual diagnostics indicated a good fi t of the model and no signifi cant deviations from the model assumptions. A level of 0.05 was considered statistically signifi cant for all other tests. SAS 9.2 was used for the statistical analysis. R software version 3.1.0 was used for the survival curves.
RESULTS
Between 1991 and 2010, a total of 117 patients over the age of 80 were diagnosed with gastroesophageal cancer at our facility. Table 1 depicts overall demographic and baseline characteristic information, highlighting the heterogeneity in presentation and treatment approach of gastroesophageal cancer, even in this highly specifi c age group. Of note, 62% of the study population was male, and 62% were between the ages of 80 and 84 at the time of inclusion. Only 29 patients (31%) presented with stage I disease, while stages II, III, and IV comprised 10%, 25%, and 34%, respectively. Th e most common site of primary malignancy was the gastric fundus (50%), followed by esophageal (30%) and gastric cardia (20%). Table 2 details the frequency of treatment modalities administered. Interestingly, 57 (49%) patients received no treatment; 25% of patients underwent surgery, 11% received chemotherapy, and 27% received radiation therapy, alone or in combination with another modality. Table 3 illustrates the eff ects baseline characteristics may have had on treatment decisions, demonstrating that most patients who received at least one of the available treatments were between the ages of 80 and 84 and had more advanced (stage 3-4) or aggressive (grade III) disease.
Th e median overall survival for patients who received treatment was signifi cantly longer relative to those without treatment, regardless of modality ( Figure 1 ). Specifi cally, the median Mortality by treatment in patients ≥80 years of age with gastroesophageal cancer seen in a 20-year period at a single medical center Tara Barnett, MD, James Mason, DO, Yolanda Munoz Maldonado, PhD, and Lucas Wong, MD overall survival for patients who underwent surgical intervention was nearly double that of those who did not (6.8 months [95% confi dence interval (CI) 3.9-19.9] vs. 3.9 months [95% CI 2.8-6.3]; P = 0.02; Figure 1a ); chemotherapy off ered an almost 4-fold overall survival benefi t (14.8 months [95% CI 5.3-30.6] vs. 3.9 months [95% CI 3.0-5.8]; P = 0.03; Figure 1b) ; and radiation therapy, a greater than 3-fold overall survival benefi t (11.1 months [95% CI 6.3-15.0] vs. 3.5 months [95% CI 2.4-4.6]; P = 0.04; Figure 1c) .
A Cox proportional hazards model was fi tted to the data. Backward, forward, and stepwise variable selection procedures chose gender, stage, and treatment with chemotherapy to be part of the model. Age group was also included in the reduced model. Th e model was statistically signifi cant (P < 0.0001). Stage and chemotherapy had coeffi cient estimates signifi cantly diff erent than 0 (Table 4 ). Gender and age group were not signifi cant. Patients without chemotherapy treatment were 2.4 times more likely to die than patients treated with chemotherapy. Patients with stage 4 disease were 5 times more likely to die than patients with stage 1, but otherwise no higher hazards for other stage combinations was identifi ed. A Cox model was fi tted to the data stratifi ed by age group. Although this model seemed to indicate an interaction between age group and gender, this interaction could not be explored due to the small sample size.
DISCUSSION
The complexity of gastrointestinal oncologic resection imposes signifi cant morbidity and mortality. A recently published study found that increasing age independently impacted No Radiation Radiation c outcome following esophagectomy, particularly mortality and discharge disposition, and patients who are at least 80 years of age considering esophagectomy should be recognized as a high-risk cohort (1) . Th e same study also concluded that age should not necessarily be a contraindication for esophagectomy, but patients over the age of 80 must be carefully selected on a case-by-case basis and serious consideration of nonoperative treatment is warranted. Similarly, a systematic review published in 2007 found no evidence of inferior survival or increased treatment-related mortality in the elderly with experimental treatments compared with younger patients (2) . Th e available data also suggest that older patients are just as willing to undergo chemotherapy as their younger counterparts, although less willing to endure severe treatment-related side eff ects (3) . Th is perspective, however, is uncommonly the standpoint from which treatment strategies for older patients are formulated. In reviewing our data, almost 50% of patients 80 years of age or older with a diagnosis of gastroesophageal cancer did not receive any of the three available modalities of treatment, even though patients who received treatment fared far better. Th is study had limitations. It failed to consider treatment bias, in that perhaps those patients selected to undergo treatment fared better because they were "healthy" enough to undergo treatment, while those who were not off ered, or opted against, treatment had inferior survival because they were more "sick" as a cohort and not candidates for therapy. It also did not refl ect quality of life during the gained months of survival in those who underwent treatment. Safety data and side eff ects were also not discussed.
With over 20 years of data, we hoped to also identify trends in mortality among the treatment and nontreatment groups over time, to perhaps demonstrate the eff ectiveness of modern therapies compared to those used 20 years ago. Unfortunately, our sample size was not suffi cient for such an analysis, but the question would be an interesting avenue of future study. Of note, within the timeframe studied, there were no major advances largely aff ecting overall survival. Th e development of minimally invasive approaches to gastroesophageal cancer resection off ered an attractive alternative to traditional transthoracic open surgery, although retrospective evaluation demonstrated identical mortality and overall surgical morbidity (4). To date, there remains no standard chemotherapy regimen for use in the neoadjuvant, combined modality setting (4). In addition, targeted therapies with known survival benefi t in gastroesophageal cancer are currently limited to trastuzumab and ramucirumab, although both were approved for use after the close of our study (5) .
Th ese data represent a signifi cant contribution to the ongoing debate over treatment strategies for those over the age of 80 diagnosed with gastroesophageal cancer. Based on these fi ndings, while age is an important predictor of overall outcome and should play a substantial role in the decision making on approach to treatment, age alone should not be the deciding factor, but one of many patient-specifi c variables that warrant consideration. As our institution, the treatment of patients over the age of 80 with gastroesophageal cancer should be considered
